Gmax Biopharm is focused on developing innovative therapeutic solutions through its advanced technology platforms, particularly in the realm of monoclonal antibodies targeting G protein-coupled receptors (GPCRs). One of their key products, GMA102, is a humanized anti-GLP-1 receptor monoclonal antibody designed to address the limitations of existing GLP-1 analog drugs used for treating type 2 diabetes and obesity. By incorporating a GLP-1 fragment, GMA102 aims to provide improved glycemic control while minimizing on-target toxicity, which has been a significant challenge with current treatments. The company has successfully completed phase II clinical studies in Australia and New Zealand and is now advancing to phase III trials in China.

In addition to GMA102, Gmax Biopharm is developing a pipeline of other monoclonal antibody candidates, including GMA106, which targets obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). The company has recently secured substantial funding to enhance its clinical trials and expedite the development of its pipeline candidates. This financial backing is expected to facilitate the creation of more innovative medicines, ultimately aiming to improve patient outcomes on a global scale. Gmax Biopharm's commitment to leveraging its GPCR monoclonal antibody platform and M-Body technology underscores its dedication to advancing therapeutic options in the biopharmaceutical landscape.

China

Gmax Biopharm LLC. has built up an in-house antibody development platform which enables the antibody screening, humanization, and engineering, in order to obtain the GPCR antibody therapeutics for unmet medical needs in cardiovascular diseases, metabolic disorders, and cancer. The company is a clinical stage biopharmaceutical company focusing on G-protein coupled receptors (GPCRs) and has developed the world's first ETa-specific monoclonal antibody. Gmax Biopharm has also partnered with Sino Biopharmaceutical Ltd. and has a strong pipeline of products in development.

Gmax Biopharm

Company Details